The trial produced evidence that the Vascular Wrap reduced the overall incidence of leg amputation and prolonged limb retention time for patients in the treatment arm relative to the control group.Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI, TSE: ANP) is a global specialty pharmaceutical and medical device company while Vascular Wrap™ is the company’s paclitaxel-eluting product for peripheral arterial disease (PAD).
According to William Hunter, MD, President and CEO of Angiotech: "We believe this is an important step forward in improving the quality of life of patients suffering from end stage peripheral arterial disease.In the said trial, the Vascular Wrap™ proved to be well tolerated, with no adverse side effects related to the use of the product.
It appears from this trial that being treated with our Vascular Wrap provides patients with an option to better manage their disease, and a much greater chance of retaining their leg for a longer period of time following synthetic bypass grafting.
The Vascular Wrap seeks to prolong the effectiveness of vascular surgery procedures, so to demonstrate a greater than 100% improvement in the duration of limb retention seems to bode well for other potential uses, like for hemodialysis graft patients."
Find more details from the press release.
Comment Preview